Natalizumab
This article needs more primary sources. (November 2018) |
Humanized (from mouse) | |
Target | alpha-4 integrin |
---|---|
Clinical data | |
Trade names | Tysabri, others |
Other names | AN100226M, Antegren |
Biosimilars | natalizumab-sztn,[1] Tyruko[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605006 |
License data |
|
Pregnancy category |
|
Intravenous | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Elimination half-life | 11 ± 4 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Molar mass | 149 kg/mol |
(what is this?) (verify) |
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat
Natalizumab, is a monoclonal antibody which targets a protein called α4β1 integrin on white blood cells involved in inflammation.[9] By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting nerve damage.[9]
The most common side effects are urinary tract infection, nasopharyngitis (inflammation of the nose and throat), headache, dizziness, nausea, joint pain and tiredness.[9]
Natalizumab was approved for medical use in the United States in 2004. It was subsequently withdrawn from the market by its manufacturer after it was linked with three cases of the rare neurological condition progressive multifocal leukoencephalopathy (PML) when administered in combination with interferon beta-1a, another immunosuppressive drug often used in the treatment of multiple sclerosis. After a review of safety information and no further deaths, the drug was returned to the US market in 2006 under a special prescription program. As of June 2009, ten cases of PML were known. However, twenty-four cases of PML had been reported since its reintroduction by October 2009, showing a sharp rise in the number of fatalities and prompting a review of the chemical for human use by the European Medicines Agency.[11] By 2010, 31 cases of PML were attributed to natalizumab while by 2018 this had risen to 757 cases.[12][13] The US Food and Drug Administration (FDA) did not withdraw the drug from the market as benefits outweigh the risks.[14] In the European Union, it has been approved only for multiple sclerosis and only by itself as the initial cases of PML, and later the fatalities, were said by the manufacturers to be linked to the use of previous medicines by the person.[15]
Medical uses
In the United states, natalizumab is
Natalizumab offers a limited improvement in efficacy compared to other treatments for multiple sclerosis, but due to the lack of information about long-term use, as well as potentially fatal adverse events, reservations have been expressed over the use of the drug outside of comparative research with existing medications.
In the European Union, natalizumab is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:
- People with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT), or[9]
- People with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses in one year, and with one or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.[9]
Adverse effects
The US prescribing information for natalizumab contains a
It was first observed in seven patients who received natalizumab in late 2008;
Common adverse effects include
About 6% of the people in studies developed long-lasting antibodies against natalizumab, which reduced the medicine's effectiveness.[9]
Mechanism of action
Natalizumab is a
Multiple sclerosis
The
Individuals with MS dosed with natalizumab demonstrated increased CD34-expressing cells, with research suggesting a peak in expression after 72 hours.[35]
Crohn's disease
The interaction of the α4β7 integrin and the
Interactions
Natalizumab appears to interact with other immune-modulating drugs to increase the risk of
Though the small number of cases precludes conclusion on the ability of natalizumab alone to induce PML, its
History
Biogen Idec announced the initiation of the first clinical trial of natalizumab as a potential cancer treatment as of September 2008.[44]
Society and culture
Legal status
Natalizumab was originally approved for treatment of
In April 2006, the Committee for Medicinal Products for Human Use recommended authorizing natalizumab to treat relapsing-remitting MS, and natalizumab was approved for medical use in the European Union in June 2006.[9][48]
Health Canada added natalizumab to Schedule F of the Food and Drug Regulations in April 2008, as a prescription drug requiring oversight from a physician.[49]
In 2007, the EMA rejected the application to market natalizumab for Crohn's disease due to concerns over its risk/benefit ratio.[50] In January 2008, the FDA approved it for the induction of remission and maintenance of remission for moderate to severe Crohn's disease.[51]
Biosimilars
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tyruko, intended for the treatment of multiple sclerosis.[52] The applicant for this medicinal product is Sandoz GmbH.[52][53] Tyruko was approved for medical use in the European Union in September 2023.[10]
In August 2023, the FDA approved approved Tyruko (natalizumab-sztn) and granted approval to Sandoz Inc.[16][54]
References
- ^ a b c d e "Tyruko (natalizumab-sztn) injection, for intravenous use" (PDF). Archived (PDF) from the original on 25 August 2023. Retrieved 25 August 2023.
- ^ "Natalizumab (Tysabri) Use During Pregnancy". Drugs.com. 24 September 2019. Archived from the original on 23 November 2020. Retrieved 4 May 2020.
- FDA. Retrieved 22 October 2023.
- ^ "Tysabri natalizumab 150 mg/1 mL injection solution pre-filled syringe (353845)". Therapeutic Goods Administration (TGA). 12 August 2022. Archived from the original on 25 August 2023. Retrieved 25 August 2023.
- ^ "Tysabri Product and Consumer Medicine Information Licence". TGA eBS. Archived from the original on 3 July 2022. Retrieved 25 August 2023.
- ^ "Tysabri Product information". Health Canada. 22 October 2009. Archived from the original on 25 August 2023. Retrieved 25 August 2023.
- ^ "Tysabri 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 14 November 2019. Archived from the original on 22 October 2020. Retrieved 4 May 2020.
- ^ a b c d e f g h i j k l "Tysabri- natalizumab injection". DailyMed. 12 August 2019. Archived from the original on 27 March 2020. Retrieved 4 May 2020.
- ^ a b c d e f g h i j "Tysabri EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 August 2020. Retrieved 4 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Tyruko EPAR". European Medicines Agency. 28 September 2023. Archived from the original on 28 October 2023. Retrieved 6 October 2023.
- ^ "Meeting highlights from the Committee for Medicinal Products for Human Use" (PDF). European Medicines Agency. 22 October 2009. Archived from the original (PDF) on 27 December 2009. Retrieved 31 August 2010.
- ^ a b c Jeffrey S (5 February 2010). "PML Risk Increases With Repeated Natalizumab Infusions: FDA". Medscape. Archived from the original on 26 January 2012. Retrieved 31 August 2010.
- ^ "Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time". ECTRIMS. 10 October 2018. Archived from the original on 28 October 2021. Retrieved 18 July 2019.
- ^ Hitti M (1 August 2008). "MS Drug Tysabri Tied to Brain Infection". WebMD. Archived from the original on 20 November 2018. Retrieved 31 August 2010.
- ^ Staton T (26 October 2009). "Tysabri safety falls under EMEA scrutiny". Fierce Pharma. Archived from the original on 23 January 2021. Retrieved 20 November 2018.
- ^ a b c d e "FDA Approves First Biosimilar to Treat Multiple Sclerosis". U.S. Food and Drug Administration (FDA) (Press release). 24 August 2023. Archived from the original on 25 August 2023. Retrieved 25 August 2023. This article incorporates text from this source, which is in the public domain.
- PMID 18354844.
- ^ PMID 18360634.
- PMID 21975773.
- ^ "Annex: Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the member states" (PDF). European Medicines Agency. Archived from the original (PDF) on 20 August 2007. Retrieved 9 March 2008.
- ^ a b Greene RT (15 December 2008). "Biogen, Elan Report Brain Illness in Tysabri Patient". Bloomberg.com. Retrieved 21 December 2008.
- PMID 15947080.
- ^ U.S. Food and Drug Administration (August 2008). "Natalizumab Injection for Intraveneous {{sic}} Use (marketed as Tysabri)". U.S. Food and Drug Administration (FDA). Archived from the original on 19 December 2008. Retrieved 22 December 2008.
- FDA. 2 May 2010. Archivedfrom the original on 24 April 2019. Retrieved 31 August 2010.
- PMID 22591293.
- S2CID 15639613.
- ^ "EMA confirms recommendations to minimise risk of brain infection PML with Tysabri". European Medicines Agency. 25 April 2016. Archived from the original on 23 January 2021. Retrieved 29 November 2019.
- ^ "FDA MedWatch - 2008 Safety Information Alerts". U.S. Food and Drug Administration (FDA). 28 February 2008. Archived from the original on 25 May 2009. Retrieved 5 April 2008.
- ^ "EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed" (PDF). European Medicines Agency. 20 March 2008. Retrieved 5 April 2008.[dead link]
- ^ "Questions and answers on Tysabri and liver injury" (PDF). European Medicines Agency. 20 March 2008. Retrieved 14 April 2008.[permanent dead link] ; lay-summary Archived 11 June 2008 at the Wayback Machine, second summary Archived 5 December 2008 at the Wayback Machine
- ^ Gross K (3 March 2008). "Multiple Sclerosis - Natalizumab (Tysabri) Can Rarely Cause Liver Problems". Archived from the original on 7 November 2016. Retrieved 5 April 2008.
- ^ Biogen Idec and Élan. Archived (PDF) from the original on 12 May 2009. Retrieved 11 April 2008.; lay summary Archived 11 June 2008 at the Wayback Machine
- PMID 17876741.
- S2CID 39916466.
- S2CID 206866717.
- PMID 15947079.
- PMID 15947078.
- ^ PMID 15947080.
- PMID 16510746.
- ^ PMID 17136224.
- S2CID 28808262.
- S2CID 25003597.
- S2CID 18131415.
- ^ "Biogen Idec testing Tysabri as a cancer treatment". The Boston Globe. 5 September 2008. Archived from the original on 29 October 2013. Retrieved 5 September 2008.
- ^ a b Pollack (9 March 2006). "F.D.A. Panel Recommends M.S. Drug Despite Lethal Risk". The New York Times. Archived from the original on 11 January 2016. Retrieved 13 March 2008.
- ^ "Errata to FDA Background document for the Tysabri (natalizumab) Advisory Committee on July 31, 2007" (PDF). U.S. Food and Drug Administration (FDA). 20 July 2007. Archived (PDF) from the original on 17 May 2017. Retrieved 9 March 2008.
- S2CID 22339176.
- ^ "European Medicines Agency: Committee for Medicinal Products for Human Use 24–27 April 2006" (PDF) (Press release). European Medicines Agency (EMA). 28 April 2006. Archived (PDF) from the original on 10 July 2007. Retrieved 2 April 2008.
- ^ "SOR/2008-101: Food and Drug Act; Regulations Amending the Food and Drug Regulations (1528—Schedule F)" (PDF). Canada Gazette Part I. 142 (8): 649. 16 April 2008. Archived (PDF) from the original on 18 August 2011. Retrieved 18 December 2010.
- ^ "Refusal CHMP assessment report for natalizumab" (PDF). European Medicines Agency. 15 November 2007. Retrieved 2 April 2008.[permanent dead link] "lay-summary" (PDF). Archived (PDF) from the original on 18 July 2009. Retrieved 4 April 2008. (78.5 KB)
- ^ "FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease". U.S. Food and Drug Administration (FDA). 14 January 2008. Archived from the original on 23 May 2009. Retrieved 9 March 2008.
- ^ a b "Tyruko: Pending EC decision". European Medicines Agency (EMA). 21 July 2023. Archived from the original on 25 August 2023. Retrieved 25 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar". PMLive. 24 July 2023. Archived from the original on 24 July 2023. Retrieved 24 July 2023.
- ^ "Biosimilar Drug Information". U.S. Food and Drug Administration (FDA). 1 November 2023. Archived from the original on 28 August 2021. Retrieved 26 November 2023.
Further reading
- Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, et al. (April 2017). "Natalizumab in Multiple Sclerosis: Long-Term Management". Int J Mol Sci. 18 (5): 940. PMID 28468254.